4 research outputs found
Traditión and innovation along the 2nd Millennium B.C. in the central Guadalquivir region: I. The funerary rituals
Una cultura debe contener un conjunto de items normalizados que nos permitan reconocerla en su extensión territorial,
y por sus cambios, establecer su secuencia interna. Con este argumento trataremos los yacimientos arqueológicos,
ya clásicos en el valle bético; en este trabajo valoraremos las necrópolis y analizaremos en otro momento la
secuencia de los poblados, durante el II milenio a.C., empleando como criterio organizador la cronología, fundamentalmente
la absoluta, cuando ello sea posible.Ancient cultures must hold an ensemble of normalized items, which allow us to locate it in its territorial area and, leaning
on its changes, to establish its sequence. According to this argument we will consider main archaeological sites
in Andalusian Valley. In this essay we will assess necropolis and analyze the village’s sequence during II B.C. using
dating as organizing criteria, absolute dating when possibl
Downregulation of both gene expression and activity of Hsp27 improved maturation of mouse oocyte in vitro
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio